{"filing":{"accession_number":"0001193125-26-326995","cik":"0001503802","ticker":"KPTI","company_name":"Karyopharm Therapeutics Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-30","primary_document":"d71318d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526326995/d71318d8k.htm"},"events":[{"id":22793,"run_id":20627,"accession_number":"0001193125-26-326995","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"The Item 8.01 disclosure covers three distinct operational/clinical developments: (1) failure of the Phase 3 XPORT-EC-042 trial to meet its primary PFS endpoint in endometrial cancer, though a trend favored selinexor in the mITT subpopulation; (2) announcement of a planned sNDA submission for selinexor in myelofibrosis based on FDA feedback on SVR35 as a surrogate endpoint; and (3) disclosure that the Company is exploring financing transactions and strategic alternatives to extend cash runway. While the trial failure and regulatory pathway update are material clinical/operational milestones, and the financing exploration signals potential financial stress, none fit neatly into the specific taxonomy categories (no earnings release, no M\u0026A completion, no going-concern language, no impairment charge). The disclosure is clearly operational/strategic in nature but spans clinical development, regulatory strategy, and capital-raising exploration, making `operational_other` the most appropriate classification.","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22845,"accession_number":"0001193125-26-326995","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The Item 8.01 disclosure covers three distinct operational/clinical developments: (1) failure of the Phase 3 XPORT-EC-042 trial to meet its primary PFS endpoint in endometrial cancer, though a trend favored selinexor in the mITT subpopulation; (2) announcement of a planned sNDA submission for selinexor in myelofibrosis based on FDA feedback on SVR35 as a surrogate endpoint; and (3) disclosure that the Company is exploring financing transactions and strategic alternatives to extend cash runway. While the trial failure and regulatory pathway update are material clinical/operational milestones, and the financing exploration signals potential financial stress, none fit neatly into the specific taxonomy categories (no earnings release, no M\u0026A completion, no going-concern language, no impairment charge). The disclosure is clearly operational/strategic in nature but spans clinical development, regulatory strategy, and capital-raising exploration, making `operational_other` the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:31.394088+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22845,"accession_number":"0001193125-26-326995","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The Item 8.01 disclosure covers three distinct operational/clinical developments: (1) failure of the Phase 3 XPORT-EC-042 trial to meet its primary PFS endpoint in endometrial cancer, though a trend favored selinexor in the mITT subpopulation; (2) announcement of a planned sNDA submission for selinexor in myelofibrosis based on FDA feedback on SVR35 as a surrogate endpoint; and (3) disclosure that the Company is exploring financing transactions and strategic alternatives to extend cash runway. While the trial failure and regulatory pathway update are material clinical/operational milestones, and the financing exploration signals potential financial stress, none fit neatly into the specific taxonomy categories (no earnings release, no M\u0026A completion, no going-concern language, no impairment charge). The disclosure is clearly operational/strategic in nature but spans clinical development, regulatory strategy, and capital-raising exploration, making `operational_other` the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:31.394088+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-07-31"}]}